Get the Stockscreener App
2.37
3.66%
-0.09
After Hours:
2.37
Neuraxis Inc stock is traded at $2.37, with a volume of 69,617.
It is down -3.66% in the last 24 hours and down -4.44% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$2.46
Open:
$2.44
24h Volume:
69,617
Relative Volume:
0.04
Market Cap:
$17.10M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-2.9383
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
-4.82%
1M Performance:
-4.44%
6M Performance:
-1.86%
1Y Performance:
-24.68%
1-Day Range:
$2.26
$2.47
1-Week Range:
$2.1963
$2.5724
52-Week Range:
$1.33
$6.20
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.37 | 23.44M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuraxis Inc Stock (NRXS) Latest News
How NeurAxis Inc. stock performs during market volatilityWeekly Profit Analysis & Weekly Chart Analysis and Trade Guides - Newser
Will breakout in NeurAxis Inc. lead to full recoveryJuly 2025 Fed Impact & Low Drawdown Investment Strategies - Newser
Sector ETF performance correlation with NeurAxis Inc.Market Sentiment Review & Stock Portfolio Risk Management - Newser
Head to Head Review: Trimedyne (OTCMKTS:TMED) and NeurAxis (NASDAQ:NRXS) - Defense World
Visual analytics tools that track NeurAxis Inc. performanceNew Guidance & Real-Time Market Trend Scan - Newser
Will NeurAxis Inc. outperform the marketWeekly Stock Summary & High Accuracy Investment Entry Signals - Newser
What moving averages say about NeurAxis Inc.Quarterly Risk Review & Real-Time Volume Trigger Notifications - Newser
Chart based analysis of NeurAxis Inc. trendsJuly 2025 Outlook & Scalable Portfolio Growth Methods - Newser
NeurAxis Inc. stock prediction for this weekWeekly Market Report & Daily Technical Stock Forecast Reports - Newser
Using Python tools to backtest NeurAxis Inc. strategies2025 Valuation Update & AI Based Buy and Sell Signals - Newser
Historical volatility pattern of NeurAxis Inc. visualizedShare Buyback & Low Drawdown Momentum Ideas - Newser
Real time breakdown of NeurAxis Inc. stock performanceWeekly Gains Summary & Real-Time Volume Spike Alerts - Newser
Chart based exit strategy for NeurAxis Inc.2025 Year in Review & Risk Controlled Swing Trade Alerts - Newser
NeurAxis, Inc. Reports Robust Q2 2025 Growth - TipRanks
What earnings revisions data tells us about NeurAxis Inc. [Earnings Risk Report]Free Weekly High Conviction Trade Ideas - Newser
Is NeurAxis Inc. Stock a Smart Buy in 2025 Investment Analysis Inside [Weekly Earnings Recap]Precise Trade Entry Recommendations - Newser
What earnings revisions data tells us about NeurAxis Inc.Fast Movement Forecast for Trading Success - Newser
NeurAxis Q2 2025: Unpacking Contradictions in Sales Strategy, Reimbursement, and Revenue Growth - AInvest
Transcript : NeurAxis, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
NeurAxis Q2 2025 Earnings Call Transcript: Key Highlights - AInvest
Earnings call transcript: Neuraxis Q2 2025 sees 46% revenue growth By Investing.com - Investing.com UK
Earnings call transcript: Neuraxis Q2 2025 sees 46% revenue growth - Investing.com
Neuraxis reports Q2 EPS (22c) vs. (42c) last year - TipRanks
NeurAxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
NeurAxis: A High-Growth Medical Tech Play with Clear Path to Profitability and Market Expansion - AInvest
NeurAxis Q2 2025 Earnings: A Catalyst for Neuromodulation Growth in Pediatric and Adult Functional Gastrointestinal Disorders - AInvest
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues - GlobeNewswire
NeurAxis Q2 rev up 46% YoY to $894,000. - AInvest
Why NeurAxis Inc. stock attracts strong analyst attentionBest Stocks for 3x Return - newsyoung.net
Using Bollinger Bands to evaluate NeurAxis Inc.High Probability Trade Plan with Indicators - Newser
Is NeurAxis Inc. stock a growth or value playFree Verified Signal From Chart Patterns - Newser
Volatility clustering patterns for NeurAxis Inc.Real Time Stock Movement and Alerts - Newser
Price action breakdown for NeurAxis Inc.Free Weekly Watchlist of High Movers - Newser
Can swing trading help recover from NeurAxis Inc. lossesLow Drawdown Picks with Weekly Updates - Newser
Analyzing recovery setups for NeurAxis Inc. investorsPredictable Income Summary for Long-Term Trades - Newser
Is NeurAxis Inc. stock entering bullish territoryWeekly Breakout Forecast with Entry Zones - Newser
Real time social sentiment graph for NeurAxis Inc.AI Generated Buy/Sell Signal Forecast - Newser
NeurAxis Inc. Testing Reversal Zone on Weekly ChartReal Time Alerts Based on AI Prediction Triggered - beatles.ru
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Cap:
|
Volume (24h):